CoChat

Histone chaperone HIRA deposits histone H3.3 onto foreign viral DNA and contributes to anti-viral intrinsic immunity

Open access
Rai, Taranjit Singh, Glass, Mandy, Cole, John J., Rather, Mohammad I., Marsden, Morgan, Neilson, Matthew, Brock, Claire, Humphreys, Ian R., Everett, Roger D., Adams, Peter D. · 2017 · Nucleic Acids Research

The DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.

Abstract

The HIRA histone chaperone complex deposits histone H3.3 into nucleosomes in a DNA replication- and sequence-independent manner. As herpesvirus genomes enter the nucleus as naked DNA, we asked whether the HIRA chaperone complex affects herpesvirus infection. After infection of primary cells with HSV or CMV, or transient transfection with naked plasmid DNA, HIRA re-localizes to PML bodies, sites of cellular anti-viral activity. HIRA co-localizes with viral genomes, binds to incoming viral and plasmid DNAs and deposits histone H3.3 onto these. Anti-viral interferons (IFN) specifically induce HIRA/PML co-localization at PML nuclear bodies and HIRA recruitment to IFN target genes, although HIRA is not required for IFN-inducible expression of these genes. HIRA is, however, required for suppression of viral gene expression, virus replication and lytic infection and restricts murine CMV replication in vivo. We propose that the HIRA chaperone complex represses incoming naked viral DNAs through chromatinization as part of intrinsic cellular immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkx771

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. HIRA chromatinizes incoming viral and other foreign DNAs. (A–D) IMR90 cells fluorescently stained with antibodies to HIRA and PML. (A) Cells were infected at MOI 5 with UV-inactivated human CMV strain AD169 (UVHCMV) or a replication deficient HSV-1 variant (in1318). Cells were fixed and stained at 24 h post-infection. (B) Quantitation of cells with HIRA localized to PML bodies from (A). Data are mean ± Standard Error Mean (SEM) from three independent experiments, P < 0.05 comparing mock versus UVHCMV and in1318. (C) Cells transiently transfected with the indicated plasmid DNAs. (D) Quantitation of cells with HIRA localized to PML bodies from (C). Data are mean ± SEM from three independent experiments, P < 0.05 comparing mock versus plasmid transfections. (E and F) IMR90 cells were infected with a replication deficient HSV-1 variant (in1318) at MOI20 (E) or transfected with pcDNA3 (F). Lysates were harvested at 24 h post-infection or transfection and DNA binding measured by anti-HIRA ChIP assay (using anti-HA as a negative control) using PCR primers binding different regions throughout the input DNA (Supplementary Table S3). For (E) data is mean ± SEM. Error bars are from technical replicates. Experiment was done three independent times with similar results. Numbers 1–6 represents six distinct regions on HSV-1 variant (in1318) genome (Supplementary Table S3). For (F) data are mean ± SEM from three independent experiments. P < 0.05 for all regions compared to control IgG (HA). Numbers 1–4 represents four distinct regions on pcDNA3 genome (Supplementary Table S3). (G) IMR90 cells were infected with lentiviruses encoding shRNAs against HIRA (shHIRA) or control (shLuc) and immunoblotted with indicated antibodies. (H) Cells from (G) were transfected with pcDNA3 and infected with purified HA-H3.3 lentivirus. Lysates were harvested at 24 h post-transfection and DNA binding measured by ChIP assay using PCR primers binding different regions throughout the input DNA. Data are mean ± SEM from three independent experiments. Numbers 1–4 represents four distinct regions on pcDNA3 genome (Supplementary Table S3). P < 0.05 for all regions comparing shLuc to shHIRA.
Figure 1. HIRA chromatinizes incoming viral and other foreign DNAs. (A–D) IMR90 cells fluorescently stained with antibodies to HIRA and PML. (A) Cells were infected at MOI 5 with UV-inactivated human CMV strain AD169 (UVHCMV) or a replication deficient HSV-1 variant (in1318). Cells were fixed and stained at 24 h post-infection. (B) Quantitation of cells with HIRA localized to PML bodies from (A). Data are mean ± Standard Error Mean (SEM) from three independent experiments, P < 0.05 comparing mock versus UVHCMV and in1318. (C) Cells transiently transfected with the indicated plasmid DNAs. (D) Quantitation of cells with HIRA localized to PML bodies from (C). Data are mean ± SEM from three independent experiments, P < 0.05 comparing mock versus plasmid transfections. (E and F) IMR90 cells were infected with a replication deficient HSV-1 variant (in1318) at MOI20 (E) or transfected with pcDNA3 (F). Lysates were harvested at 24 h post-infection or transfection and DNA binding measured by anti-HIRA ChIP assay (using anti-HA as a negative control) using PCR primers binding different regions throughout the input DNA (Supplementary Table S3). For (E) data is mean ± SEM. Error bars are from technical replicates. Experiment was done three independent times with similar results. Numbers 1–6 represents six distinct regions on HSV-1 variant (in1318) genome (Supplementary Table S3). For (F) data are mean ± SEM from three independent experiments. P < 0.05 for all regions compared to control IgG (HA). Numbers 1–4 represents four distinct regions on pcDNA3 genome (Supplementary Table S3). (G) IMR90 cells were infected with lentiviruses encoding shRNAs against HIRA (shHIRA) or control (shLuc) and immunoblotted with indicated antibodies. (H) Cells from (G) were transfected with pcDNA3 and infected with purified HA-H3.3 lentivirus. Lysates were harvested at 24 h post-transfection and DNA binding measured by ChIP assay using PCR primers binding different regions throughout the input DNA. Data are mean ± SEM from three independent experiments. Numbers 1–4 represents four distinct regions on pcDNA3 genome (Supplementary Table S3). P < 0.05 for all regions comparing shLuc to shHIRA.CC BY · PubMed Central
Figure 2. Histone chaperone HIRA responds to IFN. (A) IMR90 cells fluorescently stained with antibodies to HIRA and PML 24 h post-treatment with 2000U/ml of IFN-β. (B) Quantitation of cells with HIRA localized to PML bodies from (A) and with cells treated with 2000U/ml each of IFN-α and IFN-γ. Data are mean ± SEM from three independent experiments, P < 0.05 comparing mock versus IFN-treated cells. (C) Quantitation of cells with HIRA localized to PML bodies in cells treated with increasing dose of IFN-β as indicated. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to mock for all three doses. (D) Quantitation of cells with HIRA localized to PML bodies in primary cells (IMR90 fibroblasts, MRC5 fibroblasts, WI38 fibroblasts, human epidermal melanocytes (HEM)) treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to its mock treated for each independent cell line. (E) Quantitation of cells with HIRA localized to PML bodies in cells with indicated triggers and replicative (RS) and oncogene-induced senescent (OIS) cells. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to its mock treated for RS and OIS, p is non-significant for all other conditions. (F) Left panel: IMR90 cells treated with 2000U/ml of IFN-β and western blotted with indicated antibodies. Right Panel: genome browser representation of mRNA of HIRA in IMR90 cells treated with and without 2000U/ml of IFN-β. (G) Quantitation of cells with HIRA localized to PML bodies in cancer cell lines (A2780, U2OS, RKO, SAOS2, SW837 and HeLa) treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 for A2780, RKO and SW837 cells as compared to their mock treated cells. p is non-significant for all other cell lines. (H) Cells from (A) were fluorescently labeled with antibodies to HIRA and histone H3. (I) Quantitation of cells with UBN1 and CABIN1 localized to PML bodies in IMR90 cells treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to mock.
Figure 2. Histone chaperone HIRA responds to IFN. (A) IMR90 cells fluorescently stained with antibodies to HIRA and PML 24 h post-treatment with 2000U/ml of IFN-β. (B) Quantitation of cells with HIRA localized to PML bodies from (A) and with cells treated with 2000U/ml each of IFN-α and IFN-γ. Data are mean ± SEM from three independent experiments, P < 0.05 comparing mock versus IFN-treated cells. (C) Quantitation of cells with HIRA localized to PML bodies in cells treated with increasing dose of IFN-β as indicated. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to mock for all three doses. (D) Quantitation of cells with HIRA localized to PML bodies in primary cells (IMR90 fibroblasts, MRC5 fibroblasts, WI38 fibroblasts, human epidermal melanocytes (HEM)) treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to its mock treated for each independent cell line. (E) Quantitation of cells with HIRA localized to PML bodies in cells with indicated triggers and replicative (RS) and oncogene-induced senescent (OIS) cells. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to its mock treated for RS and OIS, p is non-significant for all other conditions. (F) Left panel: IMR90 cells treated with 2000U/ml of IFN-β and western blotted with indicated antibodies. Right Panel: genome browser representation of mRNA of HIRA in IMR90 cells treated with and without 2000U/ml of IFN-β. (G) Quantitation of cells with HIRA localized to PML bodies in cancer cell lines (A2780, U2OS, RKO, SAOS2, SW837 and HeLa) treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 for A2780, RKO and SW837 cells as compared to their mock treated cells. p is non-significant for all other cell lines. (H) Cells from (A) were fluorescently labeled with antibodies to HIRA and histone H3. (I) Quantitation of cells with UBN1 and CABIN1 localized to PML bodies in IMR90 cells treated with and without 2000U/ml of IFN-β. Data are mean ± SEM from three independent experiments, P < 0.05 as compared to mock.CC BY · PubMed Central
Figure 3. HIRA is not required for activation of IFN target genes. (A–G) IMR90 cells were stably infected with lentivirus-encoded shRNAs to HIRA (shHIRA) or control (shLuc). Cells were then treated with IFN-β either for 6 h or for 24 h as indicated in the legend. (A) Column clustered heatmap of all differentially expressed genes (FDR ≤ 5%) between shLuc 0 and 6 h and/or between shLuc 6 and 24 h. Genes are given by column and samples by row. The color intensity represents column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. (B) Scatter plot comparing the change in promoter (TSS ± 1 kb) HIRA enrichment with change in gene expression after IFN-β treatment for 24 h. Genes that change in expression significantly (FDR ≤ 5%) between shLuc 0 and 24 h are in red. All other genes are in black. HIRA ChIP-seq signals have been normalized to input control. The gray highlighted section shows genes with an expression fold ≥ 2.5 and HIRA fold ≥ 1 (also in Supplementary Figure S3D). (C) Box and jitter plots of shLuc 0 and 24 h gene expression (mean FPKM, n = 2) for the genes within the highlighted section of panel B. The P-value was calculated using a Wilcoxon rank-sum test, comparing 0–24 h. The bottom and top of the boxes correspond to the 25th and 75th percentiles respectively, and the internal band is the median. The plot whiskers correspond to the most extreme value within 1.5 × interquartile range. (D) As 3C, though measuring HIRA enrichment by ChIP-seq at 0 and 24 h. HIRA ChIP-seq signals have been normalized to input control. (E) Heatmap of the genes in A, ordered as 3A. Samples are HIRA knockdown using an shRNA hairpins (shHIRA). Genes are given by column and samples by row. The color intensity represents column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. The experiment was done in parallel with shLuc cells in (A); however to simply heatmap, only results from the knockdown cells are shown (shHIRA). Indicated time points refer to hours post IFN-β treatment. (F) Scatter plot of the genes within the highlighted section of (B), comparing shLuc to shHIRA expression. Values are mean FPKMs (n = 2). The straight-line equation derived from a linear regression is given for both comparisons. Slope of the line indicates no difference between shLuc and shHIRA. (G) Representative UCSC plot of the OAS1–3 gene cluster, showing expression by RNA-seq (top six tracks) and HIRA enrichment by ChIP-seq (bottom two tracks). The Y-axis represents library normalized read count. For the gene tracks, introns are given as horizontal lines and exons as vertical boxes.
Figure 3. HIRA is not required for activation of IFN target genes. (A–G) IMR90 cells were stably infected with lentivirus-encoded shRNAs to HIRA (shHIRA) or control (shLuc). Cells were then treated with IFN-β either for 6 h or for 24 h as indicated in the legend. (A) Column clustered heatmap of all differentially expressed genes (FDR ≤ 5%) between shLuc 0 and 6 h and/or between shLuc 6 and 24 h. Genes are given by column and samples by row. The color intensity represents column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. (B) Scatter plot comparing the change in promoter (TSS ± 1 kb) HIRA enrichment with change in gene expression after IFN-β treatment for 24 h. Genes that change in expression significantly (FDR ≤ 5%) between shLuc 0 and 24 h are in red. All other genes are in black. HIRA ChIP-seq signals have been normalized to input control. The gray highlighted section shows genes with an expression fold ≥ 2.5 and HIRA fold ≥ 1 (also in Supplementary Figure S3D). (C) Box and jitter plots of shLuc 0 and 24 h gene expression (mean FPKM, n = 2) for the genes within the highlighted section of panel B. The P-value was calculated using a Wilcoxon rank-sum test, comparing 0–24 h. The bottom and top of the boxes correspond to the 25th and 75th percentiles respectively, and the internal band is the median. The plot whiskers correspond to the most extreme value within 1.5 × interquartile range. (D) As 3C, though measuring HIRA enrichment by ChIP-seq at 0 and 24 h. HIRA ChIP-seq signals have been normalized to input control. (E) Heatmap of the genes in A, ordered as 3A. Samples are HIRA knockdown using an shRNA hairpins (shHIRA). Genes are given by column and samples by row. The color intensity represents column Z-score (based on FPKM), where red indicates more highly expressed, and blue more lowly expressed genes. The experiment was done in parallel with shLuc cells in (A); however to simply heatmap, only results from the knockdown cells are shown (shHIRA). Indicated time points refer to hours post IFN-β treatment. (F) Scatter plot of the genes within the highlighted section of (B), comparing shLuc to shHIRA expression. Values are mean FPKMs (n = 2). The straight-line equation derived from a linear regression is given for both comparisons. Slope of the line indicates no difference between shLuc and shHIRA. (G) Representative UCSC plot of the OAS1–3 gene cluster, showing expression by RNA-seq (top six tracks) and HIRA enrichment by ChIP-seq (bottom two tracks). The Y-axis represents library normalized read count. For the gene tracks, introns are given as horizontal lines and exons as vertical boxes.CC BY · PubMed Central
Figure 4. HIRA contributes to efficient suppression of viral infection. (A) Virus yield from HIRA-depleted and control IMR90 cells infected at MOI 0.01 with ICP0-null HSV-1 mutant dl1403 CMV lacZ or wt HSV-1 variant in1863. Supernatant was harvested at indicated times post infection (h p.i.) and virus titres determined by plaque assay. Data are mean +/- SD (error bars) (n = 3 biological repeats) with indicated P values. (B) HIRA-depleted and control IMR90 cells infected with ICP0-null HSV-1 mutant dl1403 at MOI 2.0. Lysates were harvested and processed at indicated time points post infection (h p.i.) (C–E) Control (CAGG-Cre-ER, WT, +tamoxifen) or Hira-deficient (CAGG-Cre-ER, Hirafl/fl, +tamoxifen) mice were infected with MCMV and spleen harvested 4 days later. Each spleen was divided into three pieces for downstream analysis. (C) Western blot analysis of WT or HIRA−/− animals showing knock out of Hira. Shown are representative western blot results from two different gels with 4 WT and 8 HIRA−/-mice. (D) mRNA abundance of IFN-β target genes by qRT-PCR. Bar chart displays mean of each IFN-β target gene mRNA abundance in WT mice compared to HIRA−/-mice, normalized to β-actin as housekeeping control. Data are mean ± SEM (error bars) (n = 4 for WT mice and n = 8 for HIRA−/-mice). *P < 0.05 (OAS1). P > 0.05 for the other six genes (OAS2, OAS3, IFITM1, IFITM2, IFITM3 and ISG15). (E) Plaque forming units measured per gram of tissue of WT or HIRA−/− mice. P-value assessed by Mann–Whitney-U test (n = 9 for WT mice and n = 18 for HIRA−/-mice).
Figure 4. HIRA contributes to efficient suppression of viral infection. (A) Virus yield from HIRA-depleted and control IMR90 cells infected at MOI 0.01 with ICP0-null HSV-1 mutant dl1403 CMV lacZ or wt HSV-1 variant in1863. Supernatant was harvested at indicated times post infection (h p.i.) and virus titres determined by plaque assay. Data are mean +/- SD (error bars) (n = 3 biological repeats) with indicated P values. (B) HIRA-depleted and control IMR90 cells infected with ICP0-null HSV-1 mutant dl1403 at MOI 2.0. Lysates were harvested and processed at indicated time points post infection (h p.i.) (C–E) Control (CAGG-Cre-ER, WT, +tamoxifen) or Hira-deficient (CAGG-Cre-ER, Hirafl/fl, +tamoxifen) mice were infected with MCMV and spleen harvested 4 days later. Each spleen was divided into three pieces for downstream analysis. (C) Western blot analysis of WT or HIRA−/− animals showing knock out of Hira. Shown are representative western blot results from two different gels with 4 WT and 8 HIRA−/-mice. (D) mRNA abundance of IFN-β target genes by qRT-PCR. Bar chart displays mean of each IFN-β target gene mRNA abundance in WT mice compared to HIRA−/-mice, normalized to β-actin as housekeeping control. Data are mean ± SEM (error bars) (n = 4 for WT mice and n = 8 for HIRA−/-mice). *P < 0.05 (OAS1). P > 0.05 for the other six genes (OAS2, OAS3, IFITM1, IFITM2, IFITM3 and ISG15). (E) Plaque forming units measured per gram of tissue of WT or HIRA−/− mice. P-value assessed by Mann–Whitney-U test (n = 9 for WT mice and n = 18 for HIRA−/-mice).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 56 references

Cited by

See all 70

Metadata

Authors
Rai, T. S., Glass, M., Cole, J. J., Rather, M. I., Marsden, M., Neilson, M., Brock, C., Humphreys, I. R., Everett, R. D., & Adams, P. D.
Affiliations
  • MRC University of Glasgow Centre for Virus Research (GB)
  • Cancer Research UK Scotland Institute (GB)
  • Cardiff University (GB)
  • Sanford Burnham Prebys Medical Discovery Institute (US)
Corresponding author
Adams, Peter D.
Venue
Nucleic Acids Research
Published
2017-09-13
Volume
45
Issue
20
Pages
11673-11683
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2754389866
Cited by
63
References
57
Citations by year
2026: 3 · 2025: 12 · 2024: 10 · 2023: 5 · 2022: 6 · 2021: 10 · 2020: 9 · 2019: 4 · 2018: 4
FWCI
1.90
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
  • Ulster University Research Portal (Ulster University) (submittedVersion, cc-by)
Funders
  • Wellcome Trust (207503/Z/17/Z)
  • Cancer Research UK (16566, A16566, C10652-A16566)
  • Research Councils UK
  • European Commission (251948)
  • University of Glasgow
  • Medical Research Council
  • National Institute on Aging (P01AG031862, AG031862)
  • National Cancer Institute (P30CA030199)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Health Sciences › Medicine › Epidemiology › Cytomegalovirus and herpesvirus research
Keywords
herpesvirus infection, cytomegalovirus, herpes simplex virus, PML nuclear bodies, interferon, viral gene expression suppression, viral replication restriction, naked plasmid DNA
MeSH terms
Promyelocytic Leukemia Protein, Animals, Cell Line, Inclusion Bodies, Chromatin, Cytomegalovirus Infections, DNA, Viral, Histones, Humans, Mice, Inbred C57BL, Protein Binding, Transcription Factors, Muromegalovirus, Herpesvirus 1, Human, Cell Cycle Proteins, Cell Line, Tumor, Histone Chaperones, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Histone chaperone HIRA deposits histone H3.3 onto foreign viral DNA and contributes to anti-viral intrinsic immunity. https://app.cochat.ai/papers/10.1093/nar/gkx771
The paper
Rai, T. S., Glass, M., Cole, J. J., Rather, M. I., Marsden, M., Neilson, M., Brock, C., Humphreys, I. R., Everett, R. D., & Adams, P. D. (2017). Histone chaperone HIRA deposits histone H3.3 onto foreign viral DNA and contributes to anti-viral intrinsic immunity. Nucleic Acids Research. https://doi.org/10.1093/nar/gkx771

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.